$STIM
Neuronetics, Inc.

2018 Form 10-K Financial Statement

#000156459019006276 Filed on March 05, 2019

View on sec.gov

Income Statement

Concept 2018 2017 Q4 2017 Q3
Revenue $52.78M $12.11M $10.49M
YoY Change 30.53%
Cost Of Revenue $12.45M $2.957M $2.636M
YoY Change 29.23%
Gross Profit $40.33M $9.151M $7.855M
YoY Change 30.93%
Gross Profit Margin 76.42% 75.58% 74.87%
Selling, General & Admin $51.93M $11.47M $8.822M
YoY Change 42.38%
% of Gross Profit 128.77% 125.29% 112.31%
Research & Development $8.230M $1.919M $1.843M
YoY Change 3.65%
% of Gross Profit 20.41% 20.97% 23.46%
Depreciation & Amortization $882.0K $140.0K $150.0K
YoY Change 47.99%
% of Gross Profit 2.19% 1.53% 1.91%
Operating Expenses $60.16M $13.38M $10.67M
YoY Change 64.96%
Operating Profit -$19.83M -$4.233M -$2.810M
YoY Change 45.75%
Interest Expense $3.688M $740.0K $807.0K
YoY Change 31.34%
% of Operating Profit
Other Income/Expense, Net -$575.0K $49.00K -$136.0K
YoY Change -261.06%
Pretax Income -$24.10M -$4.920M -$3.750M
YoY Change 49.69%
Income Tax
% Of Pretax Income
Net Earnings -$24.10M -$4.924M -$3.753M
YoY Change 50.07%
Net Earnings / Revenue -45.66% -40.67% -35.77%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.693M -$302.8K -$230.8K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $104.6M
YoY Change 259.45%
Cash & Equivalents $104.6M $29.15M $24.15M
Short-Term Investments
Other Short-Term Assets $1.800M
YoY Change 63.64%
Inventory $2.400M $2.468M
Prepaid Expenses
Receivables $5.600M $4.267M
Other Receivables $0.00
Total Short-Term Assets $114.5M $37.01M
YoY Change 209.46%
LONG-TERM ASSETS
Property, Plant & Equipment $1.400M $1.359M
YoY Change 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.200M $574.0K
YoY Change 100.0%
Total Long-Term Assets $2.500M $1.933M
YoY Change 31.58%
TOTAL ASSETS
Total Short-Term Assets $114.5M $37.01M
Total Long-Term Assets $2.500M $1.933M
Total Assets $117.0M $38.94M
YoY Change 200.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.800M $2.513M
YoY Change 52.0%
Accrued Expenses $7.100M $7.511M
YoY Change -5.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $13.60M $11.99M
YoY Change 13.33%
LONG-TERM LIABILITIES
Long-Term Debt $30.40M $29.56M
YoY Change 1.33%
Other Long-Term Liabilities $2.000M
YoY Change -16.67%
Total Long-Term Liabilities $32.40M $29.56M
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.60M $11.99M
Total Long-Term Liabilities $32.40M $29.56M
Total Liabilities $46.00M $44.45M
YoY Change 3.37%
SHAREHOLDERS EQUITY
Retained Earnings -$196.9M
YoY Change
Common Stock $4.294M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $71.00M -$192.7M
YoY Change
Total Liabilities & Shareholders Equity $117.0M $38.94M
YoY Change 200.77%

Cashflow Statement

Concept 2018 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income -$24.10M -$4.924M -$3.753M
YoY Change 50.07%
Depreciation, Depletion And Amortization $882.0K $140.0K $150.0K
YoY Change 47.99%
Cash From Operating Activities -$20.60M $270.0K -$1.930M
YoY Change 84.85%
INVESTING ACTIVITIES
Capital Expenditures -$1.010M -$270.0K -$170.0K
YoY Change 71.19%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.011M -$270.0K -$170.0K
YoY Change 70.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 97.04M 5.010M 10.00K
YoY Change 306.95%
NET CHANGE
Cash From Operating Activities -20.60M 270.0K -1.930M
Cash From Investing Activities -1.011M -270.0K -170.0K
Cash From Financing Activities 97.04M 5.010M 10.00K
Net Change In Cash 75.43M 5.010M -2.090M
YoY Change 523.0%
FREE CASH FLOW
Cash From Operating Activities -$20.60M $270.0K -$1.930M
Capital Expenditures -$1.010M -$270.0K -$170.0K
Free Cash Flow -$19.59M $540.0K -$1.760M
YoY Change 85.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 dei Entity Public Float
EntityPublicFloat
352400000
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1378000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104583000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29147000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5620000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4267000
CY2018Q4 us-gaap Inventory Net
InventoryNet
2432000
CY2017Q4 us-gaap Inventory Net
InventoryNet
2468000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1838000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1123000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
114473000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
37005000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1359000
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
503000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1743000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
146000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13559000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30395000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1940000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
86000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
151000
CY2017Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
478000
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
187136000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4292000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196946000
CY2018 us-gaap Cost Of Revenue
CostOfRevenue
12447000
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
21794000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
161000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
231000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-192652000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38938000
CY2018Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
308593000
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
308593000
CY2018Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
304958000
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
304958000
CY2018Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17744000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17744000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
231000
CY2018 us-gaap Revenues
Revenues
52776000
CY2017 us-gaap Revenues
Revenues
40433000
CY2016 us-gaap Revenues
Revenues
34228000
CY2017 us-gaap Cost Of Revenue
CostOfRevenue
9632000
CY2016 us-gaap Cost Of Revenue
CostOfRevenue
6622000
CY2017 us-gaap Gross Profit
GrossProfit
30801000
CY2016 us-gaap Gross Profit
GrossProfit
27606000
CY2017 stim Stock Issuance Costs On Issuance Of Series G Convertible Preferred Stock
StockIssuanceCostsOnIssuanceOfSeriesGConvertiblePreferredStock
175000
CY2018 stim Issuance Costs On Issuance Of Common Stock
IssuanceCostsOnIssuanceOfCommonStock
3463000
CY2018 us-gaap Operating Expenses
OperatingExpenses
60163000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-19834000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-13608000
CY2018 us-gaap Interest Expense
InterestExpense
3688000
CY2017 us-gaap Interest Expense
InterestExpense
2808000
CY2016 us-gaap Interest Expense
InterestExpense
1835000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-575000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
357000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-62000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-24097000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-16059000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-11234000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.69
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-86.34
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-76.95
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8948000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
186000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-166118000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
67000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
161000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-177124000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
496000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
187136000
CY2018 stim Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Stock Warrants Into Common Stock Warrants
AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrants
1874000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
96535000
CY2018 us-gaap Profit Loss
ProfitLoss
-24097000
CY2017 us-gaap Profit Loss
ProfitLoss
-16059000
CY2016 us-gaap Profit Loss
ProfitLoss
-11234000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
882000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
596000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
673000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1743000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
496000
CY2018 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
839000
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
108000
CY2017 stim Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
216000
CY2016 stim Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
15000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1353000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
690000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
123000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
435000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1068000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
646000
CY2018 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
237000
CY2017 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
175000
CY2016 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
156000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
606000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
788000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
734000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-52000
CY2017 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
722000
CY2016 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
391000
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1396000
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-271000
CY2018 stim Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
229000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
97038000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23845000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4896000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
75436000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12107000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3969000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29147000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17040000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21009000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104583000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1391000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1201000
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-49000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2915000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
363000
CY2018 us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
63000
CY2017 us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
5000
CY2016 us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
28000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20591000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11144000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8541000
CY2018 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1011000
CY2017 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
594000
CY2016 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
324000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1011000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-594000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
99998000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
67000
CY2017 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
14825000
CY2017 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
10000000
CY2016 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
5000000
CY2017 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1015000
CY2016 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
171000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
2786000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
2043000
CY2016 us-gaap Interest Paid Net
InterestPaidNet
1406000
CY2018 stim Transfer Of Inventory To Property And Equipment
TransferOfInventoryToPropertyAndEquipment
365000
CY2017 stim Transfer Of Inventory To Property And Equipment
TransferOfInventoryToPropertyAndEquipment
296000
CY2016 stim Transfer Of Inventory To Property And Equipment
TransferOfInventoryToPropertyAndEquipment
531000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
263000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
45000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
16000
CY2018 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
187136000
CY2018 stim Conversion Of Convertible Preferred Stock Warrants Into Common Stock Warrant
ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrant
1874000
CY2017 stim Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
55000
CY2017 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
290000
CY2016 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
135000
CY2018 us-gaap Nature Of Operations
NatureOfOperations
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.4%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>DESCRIPTION OF BUSINESS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neuronetics, Inc., or the Company, is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The Company&#8217;s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system was cleared in 2008 by the United States Food and Drug Administration, or the FDA, to treat adult patients with major depressive disorder, or MDD, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications.&nbsp;&nbsp;</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial Public Offering </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 2, 2018, the Company closed its initial public offering, or IPO, in which the Company issued and sold 6.325 million shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $17.00 per share. The Company received net proceeds of $96.5 million after deducting underwriting discounts, commissions and other offering expenses paid by the Company. The Company&#8217;s common stock is listed on the Nasdaq Global Market under the trading symbol &#8220;STIM.&#8221; In addition, immediately prior to the closing of the IPO on July 2, 2018, (i) all of the Company&#8217;s outstanding shares of convertible preferred stock converted into an aggregate 11.0 million shares of common stock; (ii) all of the Company&#8217;s outstanding warrants to purchase convertible preferred stock converted into warrants to purchase common stock; and (iii) the Company filed an amended and restated certificate of incorporation to, among other things, decrease the number of shares of common stock, $0.01 par value per share, authorized for issuance to 200.0 million and to authorize the board of directors to issue up to 10.0 million shares of &#8220;blank check&#8221; preferred stock, $0.01 par value per share.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018, the Company had cash and cash equivalents of $104.6 million and an accumulated deficit of $221.0 million. The Company incurred negative cash flows from operating activities of $20.6 million, $11.1 million and $8.5 million for the years ended December&#160;31, 2018, 2017 and 2016, respectively. The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company seeks to expand its sales and marketing initiatives to support its growth into existing and new markets and invest in additional research and development activities. The Company&#8217;s primary sources of capital to date have been from its IPO, private placements of its convertible preferred securities, borrowings under its credit facilities and revenues from sales of its products. As of December 31, 2018, the Company had $30.0 million of borrowings outstanding under its credit facility, which matures in March 2022. Management believes that the Company&#8217;s cash and cash equivalents as of December 31, 2018 and anticipated revenues from sales of its products are sufficient to fund the Company&#8217;s operations for at least the next 24 months after December 31, 2018. </p>
CY2018 us-gaap Basis Of Accounting
BasisOfAccounting
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.4%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>BASIS OF PRESENTATION </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, promulgated by the Financial Accounting Standards Board, or FASB. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the United States Securities and Exchange Commission, or SEC, requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact share-based compensation and the valuation of common stock prior to the IPO. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recapitalization</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company effected a 0.0345-for-1 reverse split of its common stock on June 14, 2018. The reverse split combined each approximately 29 shares of the Company&#8217;s issued and outstanding common stock into one share of common stock and correspondingly adjusted the conversion price of its outstanding convertible preferred stock. No fractional shares were issued in connection with the reverse split. Any fractional share resulting from the reverse split was rounded down to the nearest whole share, and in lieu of any fractional share, the Company paid in cash to the holders of such fractional shares an amount equal to the fair market value, as determined by the board of directors, of such fractional shares. All share, per share and related information presented in these financial statements and the related notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split. </p>
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-324000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3463000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
503000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
35000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the United States Securities and Exchange Commission, or SEC, requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact share-based compensation and the valuation of common stock prior to the IPO. </p>
CY2018 us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recapitalization</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company effected a 0.0345-for-1 reverse split of its common stock on June 14, 2018. The reverse split combined each approximately 29 shares of the Company&#8217;s issued and outstanding common stock into one share of common stock and correspondingly adjusted the conversion price of its outstanding convertible preferred stock. No fractional shares were issued in connection with the reverse split. Any fractional share resulting from the reverse split was rounded down to the nearest whole share, and in lieu of any fractional share, the Company paid in cash to the holders of such fractional shares an amount equal to the fair market value, as determined by the board of directors, of such fractional shares. All share, per share and related information presented in these financial statements and the related notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split. </p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Management has reviewed the financial statements of this institution and believes it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to the Company. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk principally consist of cash equivalents and accounts receivable. The Company limits its credit risk associated with cash equivalents by placing investments in highly-rated money market funds. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary, but it does not require collateral to secure amounts owed by its customers. </p>
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2018Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
6120000
CY2017Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
4684000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
500000
CY2018Q3 stim Initial Public Offering Closing Date
InitialPublicOfferingClosingDate
2018-07-02
CY2018 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
0.0345-for-1 reverse split
CY2018Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0345
CY2018Q4 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
53774000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47341000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 stim Medical Device Tax Suspension Period
MedicalDeviceTaxSuspensionPeriod
P2Y
CY2018 stim Operating Leases Expiration Year
OperatingLeasesExpirationYear
2021
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
459000
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
290000
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-271000
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
478000
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1396000
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Instruments Classified In Shareholders Equity Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3
1874000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
417000
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
153000
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
116000
CY2016 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
75000
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
274000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
343000
CY2016 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
6000
CY2017 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
42000
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
70000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3394000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3190000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2016000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1831000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4909000
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4465000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
342000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
461000
CY2018Q4 stim Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
191000
CY2017Q4 stim Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
497000
CY2018Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
127000
CY2017Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
620000
CY2018Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
629000
CY2017Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
570000
CY2018Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
606000
CY2017Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
322000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
251000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
188000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
493000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
388000
CY2018Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2018Q4 stim Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
1468000
CY2017Q4 stim Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
940000
CY2018Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1073000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1384000
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
30395000
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
29556000
CY2018 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
3700000
CY2017 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
2800000
CY2016 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
1800000
CY2018 us-gaap Interest Expense Debt
InterestExpenseDebt
2900000
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
2100000
CY2016 us-gaap Interest Expense Debt
InterestExpenseDebt
1400000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
800000
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
700000
CY2016 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
400000
CY2017Q1 stim Debt Instrument Final Payment Fee
DebtInstrumentFinalPaymentFee
1000000
CY2018Q4 stim Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
22159000
CY2017Q4 stim Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
14040000
CY2017Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
108324000
CY2018 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.090
CY2018 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105000
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3046000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.45
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.16
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2016 stim Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Weighted Average Grant Date Fair Value Of Underlying Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageGrantDateFairValueOfUnderlyingCommonStock
2.32
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.32
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.014
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.442
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
54794
CY2018Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
5.22
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P12M
CY2018Q2 stim Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue
200000
CY2018 us-gaap Defined Contribution Plan Plan Name
DefinedContributionPlanPlanName
401(k) plan
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24100000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16100000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11200000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.038
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.027
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.026
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.007
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.003
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.012
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.006
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.013
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.020
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.006
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-1.380
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.012
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.267
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.003
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.362
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
46352000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41430000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3208000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3059000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
523000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
316000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
853000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
753000
CY2018Q4 stim Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
592000
CY2018Q4 stim Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
1295000
CY2017Q4 stim Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
1530000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
951000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
253000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53774000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47341000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6400000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-16100000
CY2017Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
47341000
CY2016Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
63449000
CY2018 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
6433000
CY2017 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
6099000
CY2017 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
22207000
CY2018Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
53774000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
187000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
112000
CY2018Q4 stim Deferred Tax Assets Operating Loss Carryforwards Research And Development Credits
DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopmentCredits
3000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2013Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P93M
CY2017 stim Distribution Agreement Period
DistributionAgreementPeriod
P7Y6M
CY2017Q4 us-gaap Cost Of Revenue
CostOfRevenue
2957000
CY2017Q4 us-gaap Gross Profit
GrossProfit
9151000
CY2017Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8628000
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2837000
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1919000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
13384000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4233000
CY2017Q4 us-gaap Interest Expense
InterestExpense
740000
CY2017Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
49000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-4924000
CY2018Q4 us-gaap Interest Expense
InterestExpense
939000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
547000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
12300000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
15243000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
15035000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
17585000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4605000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5236000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4332000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5661000
CY2018Q1 us-gaap Interest Expense
InterestExpense
921000
CY2018Q2 us-gaap Interest Expense
InterestExpense
900000
CY2018Q3 us-gaap Interest Expense
InterestExpense
928000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
560000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
88000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1195000
CY2017 stim Distribution Agreement Renewal Period
DistributionAgreementRenewalPeriod
P2Y
CY2018 stim Distribution Agreements With Renewal Description
DistributionAgreementsWithRenewalDescription
The term of the distribution agreement will be automatically extended for two years unless either party gives the other party at least two years’ prior written of notice of non-renewal, except that the Company cannot decline to renew the agreement if Teijin has purchased 100% of its sales forecasts over the term of the agreement.
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q1 us-gaap Revenues
Revenues
10152000
CY2018Q2 us-gaap Revenues
Revenues
13252000
CY2018Q3 us-gaap Revenues
Revenues
13737000
CY2018Q4 us-gaap Revenues
Revenues
15635000
CY2018Q1 us-gaap Cost Of Revenue
CostOfRevenue
2457000
CY2018Q2 us-gaap Cost Of Revenue
CostOfRevenue
3245000
CY2018Q3 us-gaap Cost Of Revenue
CostOfRevenue
3034000
CY2018Q4 us-gaap Cost Of Revenue
CostOfRevenue
3711000
CY2018Q1 us-gaap Gross Profit
GrossProfit
7695000
CY2018Q2 us-gaap Gross Profit
GrossProfit
10007000
CY2018Q3 us-gaap Gross Profit
GrossProfit
10703000
CY2018Q4 us-gaap Gross Profit
GrossProfit
11924000
CY2018Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8109000
CY2018Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9835000
CY2018Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9672000
CY2018Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10648000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2636000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3078000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3238000
CY2018Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4715000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1555000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2330000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2125000
CY2018Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2222000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1360000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
299000
CY2018Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
457000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-5497000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-7496000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-4961000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-6143000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-24.43
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-30.60
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
226000
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
211000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
245000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17382000
CY2018Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17655000
CY2017Q1 us-gaap Revenues
Revenues
7526000
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-23.34
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
167000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
173000
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
194000
CY2018Q3 us-gaap Sale Of Stock Transaction Date
SaleOfStockTransactionDate
2018-07-02
CY2017Q2 us-gaap Revenues
Revenues
10308000
CY2017Q3 us-gaap Revenues
Revenues
10491000
CY2017Q4 us-gaap Revenues
Revenues
12108000
CY2017Q1 us-gaap Cost Of Revenue
CostOfRevenue
1538000
CY2017Q2 us-gaap Cost Of Revenue
CostOfRevenue
2501000
CY2017Q3 us-gaap Cost Of Revenue
CostOfRevenue
2636000
CY2017Q1 us-gaap Gross Profit
GrossProfit
5988000
CY2017Q2 us-gaap Gross Profit
GrossProfit
7807000
CY2017Q3 us-gaap Gross Profit
GrossProfit
7855000
CY2017Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6306000
CY2017Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6400000
CY2017Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6566000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1642000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1837000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2256000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2028000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2147000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1843000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
9976000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
10384000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
10665000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3988000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2577000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2810000
CY2017Q1 us-gaap Interest Expense
InterestExpense
550000
CY2017Q2 us-gaap Interest Expense
InterestExpense
711000
CY2017Q3 us-gaap Interest Expense
InterestExpense
807000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
420000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-136000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-4514000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-2868000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-3753000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-27.03
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.58
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-19.35

Files In Submission

Name View Source Status
0001564590-19-006276-index-headers.html Edgar Link pending
0001564590-19-006276-index.html Edgar Link pending
0001564590-19-006276.txt Edgar Link pending
0001564590-19-006276-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g22agdmo1tzq000001.jpg Edgar Link pending
g22agdmo1tzq000002.jpg Edgar Link pending
g22agdmo1tzq000003.jpg Edgar Link pending
g22agdmo1tzq000004.jpg Edgar Link pending
g22agdmo1tzq000005.jpg Edgar Link pending
g22agdmo1tzq000006.jpg Edgar Link pending
g22agdmo1tzq000007.jpg Edgar Link pending
g22agdmo1tzq000008.jpg Edgar Link pending
g22agdmo1tzq000009.jpg Edgar Link pending
g22agdmo1tzq000010.jpg Edgar Link pending
g22agdmo1tzq000011.jpg Edgar Link pending
g22agdmo1tzq000012.jpg Edgar Link pending
g22agdmo1tzq000013.jpg Edgar Link pending
g22agdmo1tzq000014.jpg Edgar Link pending
g22agdmo1tzq000015.jpg Edgar Link pending
g22agdmo1tzq000016.jpg Edgar Link pending
g22agdmo1tzq000017.jpg Edgar Link pending
g22agdmo1tzq000018.jpg Edgar Link pending
g22agdmo1tzq000019.jpg Edgar Link pending
g22agdmo1tzq000020.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stim-10k_20181231.htm Edgar Link pending
stim-20181231.xml Edgar Link completed
stim-20181231.xsd Edgar Link pending
stim-20181231_cal.xml Edgar Link unprocessable
stim-20181231_def.xml Edgar Link unprocessable
stim-20181231_lab.xml Edgar Link unprocessable
stim-20181231_pre.xml Edgar Link unprocessable
stim-ex231_213.htm Edgar Link pending
stim-ex311_391.htm Edgar Link pending
stim-ex312_389.htm Edgar Link pending
stim-ex321_390.htm Edgar Link pending